Radiotherapy and Nuclear Medicine

Introduction

Ionising radiation can be used to make an image or to treat disease. The goals differ: imaging aims to obtain useful information while controlling exposure, while radiotherapy aims to deliver a prescribed effect to targeted tissue. Nuclear medicine can include both diagnostic tracers and therapeutic radiopharmaceuticals. Knowing where the radioactive material is located distinguishes some methods but does not by itself reveal whether the purpose is diagnosis or treatment.

Core explanation

Diagnostic nuclear medicine administers a radiopharmaceutical whose emissions can be detected to show distribution or function in the body. A gamma camera or PET scanner records signals associated with the labelled compound. The amount and emission type are chosen to obtain an adequate image while managing patient exposure. A scan is a measurement, not an attempt to damage the tissue being imaged. Other diagnostic imaging methods, such as ordinary X-ray radiography, may use an external X-ray tube rather than an administered radiopharmaceutical and should not all be called nuclear medicine.

Radiotherapy uses ionising radiation to damage target tissue as part of a treatment plan. An external-beam system directs radiation from equipment outside the patient toward a planned region. Brachytherapy places sealed radioactive sources in or near a target for certain treatments. Radionuclide therapy administers a radioactive medicine that reaches or binds to selected tissue and deposits radiation energy there. These methods differ in source location and delivery, though all require careful planning and monitoring.

Therapeutic radiopharmaceuticals combine chemistry and nuclear properties. A carrier or compound influences where the radionuclide accumulates; its emitted radiation can deliver energy to cells in that region. Some treatments use beta-emitting nuclides, and other approaches can use alpha emitters. Selection depends on clinical purpose, biological uptake, emission energy and range, half-life and dose to target and non-target tissues. A short particle range can help localise energy deposition but is not by itself proof that surrounding tissue receives no dose.

Activity in Bq describes how many nuclear transformations occur per second in the administered or implanted material. It is not the same as absorbed dose in Gy, which describes energy deposited per kilogram in a tissue. Two patients or organs may receive different doses from the same administered activity because uptake and clearance differ. Dosimetry and treatment planning connect source properties to the relevant tissue energy deposition and are performed by qualified clinical teams.

The distinction between irradiation and contamination still applies. An external beam can irradiate tissue without placing radioactive material in the body. A radiopharmaceutical intentionally introduces radioactive material for a controlled medical purpose, so emissions arise from where that material travels. A sealed brachytherapy source may be placed internally but remains contained. Those facts should be described precisely; “internal radiation” is not one single method.

Medical use involves balancing benefit and risk. Diagnostic imaging should answer a justified clinical question, while treatment planning seeks effective target exposure with controlled effects on healthy tissue. It is inaccurate to say all radiation is either harmless because it is medical or unacceptable because it ionises. The quantitative decisions are specific to a patient and procedure and go beyond the simple nuclear equations in this course.

Half-life influences logistics and exposure duration but does not determine treatment effectiveness alone. A long-lived nuclide may persist after the useful interval; a very short-lived one may decay before it reaches target tissue. The emitted radiation's energy and range, chemistry and biological clearance are also needed. The lesson's calculations can compare fractions remaining, but they cannot prescribe a clinical activity or dose.

Step-by-step reasoning

1. Identify whether the purpose is diagnosis or treatment. 2. Determine whether radiation comes from external equipment, a sealed placed source or an administered radiopharmaceutical. 3. Name what the instrument measures or what tissue is intended to receive energy. 4. Keep activity in Bq distinct from absorbed dose in Gy. 5. Explain how chemistry, half-life and emission type affect the plan without making clinical prescriptions.

Visual explanation

Draw three panels: an external beam aimed at a planned region; a labelled tracer inside the body sending photons to a camera; and a therapeutic radiopharmaceutical accumulating near a target and depositing energy locally. Under each, label source location, purpose and measured or planned outcome. Use a separate small box “Bq = decays/s; Gy = J/kg” to distinguish quantities.

Real-world analogy

A flashlight can help inspect a room, while a carefully focused tool can act on a selected spot. The first resembles information gathering and the second an intended treatment effect. This analogy is limited because radiation deposits energy in tissue and demands quantitative medical planning rather than casual control.

Real-world example

A technetium-99m-labelled compound may be used for imaging by detecting photons leaving the patient. A therapeutic radiopharmaceutical, in contrast, is selected to deliver radiation to a disease-related target. The same general field of nuclear medicine can therefore include diagnostic and therapeutic applications, with different selection and dosimetry goals.

Why?

Why can the same activity in Bq lead to different organ doses? Activity counts decays in the source, but dose depends on where the source is, how long it remains, what emissions deposit energy and how much tissue mass receives that energy. Biological distribution turns a source number into different exposure patterns.

Common misconception

“Nuclear medicine always means imaging, and radiotherapy always means an external beam.” Nuclear medicine can include radionuclide treatment, and radiation treatment can be delivered externally or with material placed in or administered to the patient. Specify the method and purpose.

Worked example

Two hypothetical procedures administer 100 MBq of different radiopharmaceuticals. Procedure A uses a photon-emitting tracer for imaging; Procedure B uses a particle-emitting compound intended to deposit energy in a target. Both have initial activity 100 million decays/s, but the number alone does not show equal tissue dose, image quality or treatment effect. The emissions, target uptake, residence times and absorbed-energy calculations differ. Concluding “same Bq, same dose” would confuse nuclear transformations with deposited energy.

Quick check

1. Which quantity describes energy deposited per kilogram of tissue: Bq or Gy? Answer: Gray (Gy) describes absorbed energy per kilogram; Bq describes source decays per second.

Exam focus

Separate imaging from treatment and identify source location. Explain activity versus dose with units. Describe external-beam therapy and radiopharmaceutical methods at a conceptual level without assuming every medical radiation use administers radioactive material.

Advanced insight

Modern “theranostic” approaches can pair related diagnostic and therapeutic radiopharmaceuticals that target the same biological feature while using nuclides suited to imaging or treatment. The pairing helps estimate target distribution and plan therapy, but chemical similarity does not remove the need for individual dosimetry and clinical evaluation.

Summary

Diagnostic nuclear medicine uses radioactive tracers for information; radiotherapy uses ionising radiation for treatment. External beams, sealed sources and administered radiopharmaceuticals place the source differently. Activity, emitted radiation and tissue dose are distinct, so safe and effective use requires procedure-specific planning.

Practice questions

1. Is an external X-ray image necessarily a nuclear medicine scan? Answer: No. An X-ray tube is an external source; nuclear medicine imaging uses an administered radiopharmaceutical. 2. What distinguishes 100 MBq from an absorbed dose value? Answer: 100 MBq is 100 million decays per second; absorbed dose measures radiation energy deposited per kilogram of tissue. 3. Can a radiopharmaceutical be used for treatment rather than imaging? Answer: Yes. Therapeutic radiopharmaceuticals deliver radiation to selected tissue, with chemistry and dosimetry guiding their use.